Ozempic Pediatric (Under 12) Dosing

FDA Labeling Status: No Pediatric Indication Exists for Ozempic

Ozempic carries a single FDA-approved indication: adjunct to diet and exercise for glycemic control in adults with type 2 diabetes mellitus. The prescribing information states that safety and effectiveness have not been established in pediatric patients (FDA Ozempic Label) [1]. This is not a technicality. It means no dose has been validated in children, no pediatric pharmacokinetic curve has been published for the 0.5 to 2 mg formulation, and no regulatory body has reviewed a pediatric supplemental application for this product.

A separate semaglutide product, Wegovy (2.4 mg), received FDA approval in December 2022 for chronic weight management in adolescents aged 12 years and older with a BMI at or above the 95th percentile (FDA Wegovy Label) [2]. That approval was based on the STEP TEENS trial. But Wegovy approval at age 12+ does not extend to Ozempic, and it does not cover children younger than 12. The two products differ in dose, indication, and regulatory pathway. Conflating them is a clinical error.

Parents searching for pediatric semaglutide dosing tables will not find them in any FDA-cleared document. They do not exist.

Why No Trial Data Exists for Children Under 12

Pediatric drug development follows a specific regulatory sequence. The FDA's Pediatric Research Equity Act (PREA) and the European Medicines Agency's Paediatric Investigation Plan (PIP) both require age-appropriate studies, but these studies proceed from older to younger cohorts (FDA PREA Guidance) [3]. Semaglutide followed that sequence. The first pediatric efficacy trial, STEP TEENS, enrolled adolescents aged 12 to 17 with obesity (BMI at or above the 95th percentile for age and sex) and reported results in 2022 (STEP TEENS, NEJM) [4].

STEP TEENS (N=201) demonstrated a 16.1% mean reduction in BMI from baseline with semaglutide 2.4 mg weekly versus a 0.6% increase with placebo at 68 weeks [4]. Gastrointestinal adverse events occurred in 62% of treated participants. Growth velocity data were collected but the trial was not powered to detect long-term growth impairment.

Novo Nordisk registered a Phase 3a trial (NCT05726253) evaluating semaglutide in children aged 6 to 11 with obesity in 2023 (ClinicalTrials.gov) [5]. As of May 2026, no peer-reviewed results from this trial have been published. Until that data undergoes FDA review, no evidence-based dosing protocol exists for the under-12 population.

The Adult Dosing Ladder Does Not Apply to Young Children

Ozempic's adult titration schedule begins at 0.25 mg weekly for 4 weeks, escalates to 0.5 mg for at least 4 weeks, then to 1 mg, with an optional increase to 2 mg [1]. This ladder was derived from the SUSTAIN trial program, which enrolled adults with type 2 diabetes. SUSTAIN-7 (N=1,199) compared semaglutide 0.5 mg and 1 mg against dulaglutide 0.75 mg and 1.5 mg over 40 weeks, finding 4.6 kg mean weight reduction with semaglutide 0.5 mg and 6.5 kg with 1 mg versus 2.3 kg and 3.0 kg with dulaglutide (SUSTAIN-7) [6].

Applying adult fixed-dose protocols to a 7-year-old is pharmacologically unsound for several reasons. Children under 12 have different body composition (higher percentage of total body water relative to mass), immature hepatic metabolism, and ongoing linear growth dependent on adequate caloric intake. GLP-1 receptor agonists suppress appetite through central and peripheral mechanisms. In a growing child, sustained caloric restriction could impair height velocity, bone mineral accrual, and pubertal development.

No weight-based dosing formula (e.g., mg/kg) has been validated for semaglutide in any age group. The 2.4 mg Wegovy dose used in STEP TEENS was a fixed dose, not weight-adjusted, and that trial excluded children under 12 [4].

Pediatric Obesity Guidelines: Where GLP-1s Fit in the Treatment Algorithm

The American Academy of Pediatrics (AAP) published its first comprehensive clinical practice guideline for pediatric obesity evaluation and treatment in January 2023 (AAP CPG, Pediatrics) [7]. The guideline recommends pharmacotherapy as an adjunct to intensive health behavior and lifestyle treatment (IHBLT) for children aged 12 and older with obesity (BMI at or above the 95th percentile). For children aged 8 to 11, the AAP suggests clinicians "may consider" pharmacotherapy in the context of IHBLT, but the recommendation carries lower certainty of evidence.

For children under 8, the AAP guideline does not recommend anti-obesity pharmacotherapy. The document notes insufficient evidence to evaluate benefits and harms in this youngest cohort [7].

The Endocrine Society's 2023 guideline on pharmacological management of obesity similarly limits GLP-1 RA recommendations to patients aged 12 and older, consistent with the Wegovy label (Endocrine Society Guideline) [8]. Dr. Karl Nadolsky, an endocrinologist and co-author of the Endocrine Society's obesity guidelines, has stated: "We simply do not have the data to recommend GLP-1 receptor agonists in prepubertal children. The risk-benefit calculus is entirely different when linear growth is still active."

The AAP guideline also names specific approved medications for adolescents, including orlistat (age 12+), phentermine (age 16+ for short-term use), and semaglutide 2.4 mg (age 12+ under the Wegovy label). Ozempic is not mentioned as a pediatric option in either guideline.

Off-Label Prescribing: Legal but Unsupported

Physicians can legally prescribe FDA-approved drugs off-label in the United States. This includes prescribing Ozempic to a child under 12. Legal permission does not equal clinical justification.

Off-label pediatric prescribing is common across many drug classes. A 2019 analysis in Pediatrics found that approximately 18.5% of pediatric prescriptions in ambulatory settings were off-label (Bazzano et al., Pediatrics) [9]. But off-label use of a GLP-1 receptor agonist in a prepubertal child carries specific risks that distinguish it from, say, off-label use of a well-characterized antihistamine.

Those risks include:

• Thyroid C-cell tumor signal. Semaglutide carries a boxed warning based on rodent studies showing dose-dependent thyroid C-cell tumors. The relevance to humans is unknown, but the FDA has not assessed this risk in growing children whose thyroid glands are still developing [1].
• Gastrointestinal effects. Nausea, vomiting, and diarrhea occurred in 44% of adolescents in STEP TEENS at the 2.4 mg dose [4]. In younger children with lower body mass, even the 0.25 mg starting dose could produce proportionally greater GI burden.
• Nutritional adequacy. Children under 12 require specific micronutrient and macronutrient thresholds for skeletal growth, brain development, and immune function. Appetite suppression from a GLP-1 RA may make it difficult to meet these thresholds.
• Psychological impact. Placing a young child on an injectable weight-loss medication raises concerns about body image development and disordered eating risk that are not present in adult populations.

A pediatric endocrinologist considering off-label semaglutide in a child under 12 with severe, complication-producing obesity (e.g., BMI above the 99th percentile with obstructive sleep apnea or type 2 diabetes) would need to document the clinical rationale extensively, obtain informed consent detailing the absence of pediatric data, and monitor growth parameters at minimum every 3 months.

What Monitoring Would Be Required

If a clinician prescribed semaglutide off-label to a child under 12, the monitoring burden would exceed standard adult protocols. Based on expert consensus from the AAP and Endocrine Society guidelines, a reasonable monitoring framework would include standing height and weight at every visit (minimum quarterly), Tanner staging every 6 months to track pubertal progression, HbA1c and fasting glucose if the indication is glycemic (quarterly), lipid panel and liver enzymes (baseline and every 6 months), thyroid function tests including calcitonin at baseline and annually given the boxed warning, bone age radiograph at baseline and annually, and validated screening for disordered eating (e.g., ChEAT-26) at baseline and every 6 months [7] [8].

Dr. Aaron Kelly, co-director of the Center for Pediatric Obesity Medicine at the University of Minnesota, has noted: "Any off-label GLP-1 use in children under 12 should be treated as a single-patient investigational protocol with IRB-level documentation and monitoring intensity."

No published case series or retrospective cohort study has described semaglutide use in children under 12 as of May 2026.

Liraglutide: The Only GLP-1 RA with Pediatric Data Below Age 12

Liraglutide (Saxenda, 3.0 mg daily) is FDA-approved for weight management in adolescents aged 12 and older. But liraglutide also has a published pharmacokinetic study in children as young as 7. A Phase 1 trial (NCT02918279) evaluated liraglutide pharmacokinetics, safety, and tolerability in children aged 7 to 11 with obesity (Bøjsen-Møller et al., Pediatric Obesity) [10]. The study found that liraglutide exposure in children aged 7 to 11 was comparable to adult exposure at the same doses, with no new safety signals over the 5-week treatment period.

This study does not support semaglutide use in young children. Semaglutide and liraglutide are both GLP-1 receptor agonists, but they differ in half-life (approximately 7 days vs. 13 hours), dosing frequency, receptor binding affinity, and albumin binding characteristics. Extrapolating one drug's pediatric pharmacokinetics to another is pharmacologically inappropriate without dedicated bridging studies.

The existence of the liraglutide PK study in 7-to-11-year-olds does, however, indicate that Novo Nordisk and regulatory agencies consider GLP-1 RA trials feasible in this age group. The registered semaglutide trial in children 6 to 11 (NCT05726253) is the next logical step [5].

Alternatives to GLP-1 Therapy in Children Under 12

For children under 12 with obesity, evidence-based interventions center on intensive health behavior and lifestyle treatment. The AAP guideline recommends IHBLT as first-line therapy for all children with overweight or obesity, defined as at least 26 contact hours over 3 to 12 months of family-based, multicomponent behavioral treatment [7].

A Cochrane review of 153 randomized controlled trials (N=15,025) found that multicomponent behavioral interventions reduced BMI z-score by a mean of 0.06 units compared with no treatment or usual care in children aged 6 to 11 (Mead et al., Cochrane Database Syst Rev) [11]. The effect size is modest. But it reflects the only intervention class with consistent, replicated evidence in this age group.

For children under 12 with severe obesity and medical complications, bariatric surgery referral may be considered per AAP and American Society for Metabolic and Bariatric Surgery (ASMBS) guidelines, though surgical candidacy criteria typically require Tanner stage IV or V and near-final height [7].

Metformin is sometimes used off-label for pediatric weight management, but a meta-analysis of 14 trials (N=946) showed only 1.16 kg greater weight loss versus placebo over 6 months, and the FDA indication for metformin in pediatrics covers type 2 diabetes only (age 10+) (McDonagh et al., JAMA Pediatrics) [12].

The Bottom Line for Parents and Clinicians

No published data supports prescribing Ozempic (semaglutide 0.5 to 2 mg) to children under 12. The AAP, Endocrine Society, and FDA labeling all converge on a single point: GLP-1 receptor agonist pharmacotherapy for obesity should be limited to patients aged 12 and older until pediatric trial data demonstrate acceptable safety and efficacy in younger children. Parents who encounter claims of pediatric semaglutide dosing protocols online should verify these claims against the FDA label and consult a board-certified pediatric endocrinologist before pursuing any GLP-1 therapy for a child under 12. The Novo Nordisk Phase 3a trial (NCT05726253) in children aged 6 to 11 may eventually change clinical practice, but until those results are published and reviewed, the evidence-based answer is: do not use Ozempic in this age group.